PARTICLE THERAPY APPEARS TO BE A COST-EFFECTIVE TREATMENT MODALITY AS OPPOSED TO CONVENTIONAL 3D RADIOTHERAPY AND STEREOTACTIC BODY RADIOTHERAPY FOR INOPERABLE STAGE I NON-SMALL CELL LUNG CANCER PATIENTS, BUT MORE EVIDENCE IS NEEDED
Version 2 2024-06-04, 06:22Version 2 2024-06-04, 06:22
Version 1 2019-07-11, 13:26Version 1 2019-07-11, 13:26
conference contribution
posted on 2024-06-04, 06:22authored byJ Grutters, M Pijis-Johannesma, M Joore, D De Ruysscher, A Dekker, Anna PeetersAnna Peeters, S Reimoser, J Severens, P Lambin
PARTICLE THERAPY APPEARS TO BE A COST-EFFECTIVE TREATMENT MODALITY AS OPPOSED TO CONVENTIONAL 3D RADIOTHERAPY AND STEREOTACTIC BODY RADIOTHERAPY FOR INOPERABLE STAGE I NON-SMALL CELL LUNG CANCER PATIENTS, BUT MORE EVIDENCE IS NEEDED